Physician profile
John Oghene
NPI 1528421609
$3,849.35
in general payments reported to CMS, 2019-2025
24 companies · $3,107 in 2025
The $3,107 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $742 · 2025: $3,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,749 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,749.36 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $920.33 | 2024-2025 | |
| Amgen INC. | $618.77 | 2024-2025 | Evenity, Tavneos, Otezla |
| Ucb, INC. | $376.61 | 2024-2025 | Bimzelx, Cimzia |
| Vertex Pharmaceuticals Incorporated | $332.54 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.51 | 2024-2025 | Jardiance, Ofev |
| Janssen Biotech, INC. | $222.71 | 2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $216.82 | 2025 | Acthar |
| Glaxosmithkline, LLC. | $120.41 | 2024-2025 | Benlysta |
| Genzyme Corporation | $117.46 | 2024-2025 | |
| Organon LLC | $89.42 | 2024-2025 | Hadlima, Renflexis |
| Novartis Pharmaceuticals Corporation | $80.21 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $79.65 | 2024-2025 | Orencia |
| Fresenius Kabi USA, LLC | $78.43 | 2025 | Tyenne |
| Xeris Pharmaceuticals, INC. | $64.87 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $51.05 | 2025 | Saphnelo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $49.03 | 2025 | Wegovy, Ozempic |
| Sandoz INC. | $46.92 | 2024-2025 | Hyrimoz |
| Recordati_rare_diseases_inc. | $32.93 | 2025 | Isturisa |
| Pfizer INC. | $18.04 | 2025 | |
| Lilly USA, LLC | $17.59 | 2025 | Mounjaro, Zepbound |
| Sequel Med Tech, LLC | $17.58 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $17.46 | 2025 | Imcivree |
| Cequr Corporation | $15.45 | 2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $14.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Oghene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.